Soluble CD14 antigen
AssigneeMochida Pharmaceuticals Co., Ltd.
InventorsShoji Furusako, Kamon Shirakawa, Jiro Hirose
Life of this patent
Estimating the term…
Abstract
There are provided a soluble CD14 antigen which is a novel in vivo protein useful as a marker for diagnosing sepsis and has the following characteristic features 1) to 3): 1) a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions; 2) an amino acid sequence in which the amino acid sequence of SEQ ID NO:1 is present on its N terminal; and 3) ability to specifically bind to an antibody prepared by using a peptide comprising 16 amino acid residues described in SEQ ID NO:2 for the antigen; and a recombinant soluble CD14 fragment.
Claims12
An isolated soluble CD14 antigen, which consists of the amino acid sequence from position 1 to any one of positions 59 to 90 of the amino acid sequence of SEQ ID NO:3, wherein said soluble CD14 antigen has no ability to specifically bind to 3C10 antibody, ATCC No. TIB-228 and no ability to bind to LPS, and wherein said isolated soluble CD14 antigen has a molecular weight of 13±2 kDa when measured b SDS-PAGE under non-reducing conditions.
An isolated soluble CD14 antigen, which consists of the amino acid sequence from any one of positions 1 to 6 to any one of positions 59 to 90 of the amino acid sequence of SEQ ID NO:3, wherein said soluble CD14 antigen is capable of being obtained from human serum;
- has no ability to specifically bind to 3C10 antibody, ATCC No. TIB-228;
- has no ability to bind to LPS
- has a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions,
- has no ability to specifically bind to MEM-18 antibody;
- and
- specifically binds to an antibody which binds a peptide consisting of the amino acid sequence of SEQ ID NO:2.
An isolated recombinant soluble CD14 fragment, which consists of the amino acid sequence from any one of positions 1 to 17 to any one of positions 59 to 90 of the amino acid sequence of SEQ ID NO:3;
- wherein said recombinant soluble CD14 fragment has no ability to specifically bind to 3C10 antibody, ATCC No. TIB-228 and MEM-18 antibody, and no ability of binding to LPS, and
- wherein said recombinant soluble CD14 fragment has a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions.
Dependencies are inferred from the claim text.